drugset / Trial / NCT05725343
A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
Phase 3
Terminated
350 enrolled
Mario Negri Institute for Pharmacological Research
Novartis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Randomized phase III, double-blind, placebo-controlled, multicenter clinical trial.
Timeline
- Start
- 2022-02-03
- Primary completion
- 2022-04-03
- Completion
- 2022-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 200 mg | Subcutaneous |